Business
business

Automakers say China’s rare earth magnets stranglehold could cause massive production issues in weeks

Automakers are only about two years past the global semiconductor shortage that squeezed production.

Now, a new potentially major supply issue is brewing, caused by China’s control over rare earth magnets.

Rare earth magnets are used throughout modern vehicles, including in motors, windshield wipers, doors, and window switches. China, which controls about 90% of the world’s supply of the elements, is said to have excessively slowed its export since early April.

According to reporting from The Wall Street Journal, impending factory shutdowns are causing some US automakers to weigh shocking solutions like moving EV motor production to China or even shipping US-built motors to China, installing the magnets, and shipping them back.

Last month, the shortage caused a Ford plant in Chicago to halt production for a week.

“It’s a major issue for the industry. I don’t think the industry is very well prepared to deal with it,” Bank of America’s senior auto analyst, John Murphy, said at a virtual media event on Wednesday. “Over time, if it’s not solved, it’s going to become a very expensive problem. I mean, I think it’s kind of a new potential shock to the system.”

Rare earth magnets are used throughout modern vehicles, including in motors, windshield wipers, doors, and window switches. China, which controls about 90% of the world’s supply of the elements, is said to have excessively slowed its export since early April.

According to reporting from The Wall Street Journal, impending factory shutdowns are causing some US automakers to weigh shocking solutions like moving EV motor production to China or even shipping US-built motors to China, installing the magnets, and shipping them back.

Last month, the shortage caused a Ford plant in Chicago to halt production for a week.

“It’s a major issue for the industry. I don’t think the industry is very well prepared to deal with it,” Bank of America’s senior auto analyst, John Murphy, said at a virtual media event on Wednesday. “Over time, if it’s not solved, it’s going to become a very expensive problem. I mean, I think it’s kind of a new potential shock to the system.”

More Business

See all Business
business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims oral semaglutide

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

$1.3M

There’s still plenty of money to be made in brainrot. The top 1,000 Roblox creators earned an average of $1.3 million in 2025 — up 50% from the year prior — according to CEO Dave Baszucki on the company’s fourth-quarter earnings call.

Roblox paid out $1.5 billion to creators last year, meaning its top 1,000 creators took home about 87% of the total pool.

Like other creator economy giants, Roblox rewards its biggest creators for their contributions to user engagement. Creator-made titles like “Grow a Garden” and “Steal a Brainrot” substantially boosted playing time over the course of the year. In September, the company increased its developer exchange rate, or the ratio of in-game currency to cash payout, by 8.5%.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.